Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDasari, Arvind
dc.contributor.authorSobrero, Alberto
dc.contributor.authorYao, James
dc.contributor.authorYoshino, Takayuki
dc.contributor.authorSchelman, William
dc.contributor.authorYang, Zhao
dc.contributor.authorTabernero Caturla, Josep
dc.date.accessioned2022-02-22T09:29:30Z
dc.date.available2022-02-22T09:29:30Z
dc.date.issued2021-08
dc.identifier.citationDasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Futur Oncol. 2021 Aug;17(24):3151–3162.
dc.identifier.issn1479-6694
dc.identifier.issn10.2217/fon-2021-0202
dc.identifier.urihttp://hdl.handle.net/11351/7060
dc.descriptionClinical development; Fruquintinib; Refractory metastatic colorectal cancer
dc.description.abstractFruquintinib, a novel, highly selective, small-molecule tyrosine kinase inhibitor of VEGF receptors (VEGFRs)-1, -2 and -3, is approved in China for the treatment of metastatic colorectal cancer. FRESCO-2, a global, randomized, double-blind, placebo-controlled, Phase III study, is investigating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Key inclusion criteria include: progression on or intolerance to TAS-102 and/or regorafenib; and prior treatment with approved chemotherapy, anti-VEGF therapy, and, if RAS wild-type, anti-EGFR therapy. Approximately 687 patients will be randomized 2:1 to fruquintinib plus best supportive care or placebo plus best supportive care. Primary and key secondary end points are overall survival and progression-free survival, respectively. FRESCO-2 is enrolling in the USA, Europe, Australia and Japan.
dc.language.isoeng
dc.publisherFuture Science Group
dc.relation.ispartofseriesFuture Oncology;17(24)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectRecte - Càncer - Tractament
dc.subjectCòlon - Càncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents
dc.subject.meshTreatment Outcome
dc.titleFRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.2217/fon-2021-0202
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Dasari A, Yao J] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA. [Sobrero A] Ospedale Policlinico San Martino – IRCCS, Largo R. Benzi n.10, Ospedale Policlinico San Martino, Padiglione ex Microbiologia, Piano Terra Levante, 16132, Genova, Italy. [Yoshino T] Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 270-8577, Japan. [Schelman W] Clinical Development, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Yang Z] Biostatistics, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain
dc.identifier.pmid33993740
dc.identifier.wos000651079000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record